Strategic partnerships Aligos has active collaboration history with Amoytop Biotech and has recently licensed pevifoscorvir sodium in Greater China, indicating openness to regional partnerships and co-development opportunities that could be leveraged to expand in adjacent markets.

China market focus Recent license deal to develop and commercialize a HBV asset in Greater China signals a growing emphasis on the Chinese market, presenting potential sales avenues for localized manufacturing, regulatory support services, and regional commercialization partnerships.

HBV portfolio momentum Multiple HBV programs and partnerships (ALG-170675 collaboration; ongoing pevifoscorvir sodium activities) suggest strong demand for antisense and viral disease therapies, offering cross-sell opportunities to pharma companies seeking HBV pipeline enhancement.

Leadership expansion Recent appointments in senior commercial and business development roles indicate a strategic push to upscale market access, territory planning, and strategic alliances, creating openings for external BD collaborations and distribution partnerships.

Clinical and data footprint Active participation in major hepatology conferences and positive data dissemination create doors for sponsored research, investigator-initiated studies, and co-promotion discussions with contract research organizations and other liver disease stakeholders.